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Background: To evaluate the prognostic value of endotoxin activity assay (EAA) in adult patients with suspected or
proven severe sepsis after cardiac surgery
Methods: Blood samples taken from 81 patients immediately after the diagnosis of severe sepsis were tested with
the EAA. Patients were divided into 3 groups: low (<0.4, n = 20), moderate (0.4-0.59, n = 35) and high (≥0.6, n = 26)
EAA levels.
Results: Gram-negative bacteraemia was found in 19/55 (35%) of cases with ЕАА <0.6 and in 11/26 (42%) of cases
with higher ЕАА, p = 0.67. Mortality at 28 days in Groups 1, 2 and 3 was 20%, 43% and 54%, respectively. Patients
with an EAA higher than 0.65 had a higher 28-day mortality than those with lower EAA values (18/26 – 69% vs.
19/55 – 34.5%; p = 0.0072). ROC analysis for the prediction of 28-day mortality revealed an AUC for APACHE II
scores, EAA and PCT of 0.81, 0.73 and 0.66, respectively.
Conclusions: EАА might be useful for recognising patients who have an increased risk of mortality due to severe
sepsis.
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The role of endotoxin in the pathogenesis of sepsis is
well-known [1]. Endotoxin activates the release of cyto-
kines and other biologically active components. Develop-
ing of systemic inflammatory response syndrome leads to
disturbances in membrane permeability together with
multiple organ dysfunction syndrome and, often, death.
Therefore, clinicians require a precise laboratory diagnos-
tic tool for endotoxin detection for the timely initiation of
specific treatment.
Quantitative techniques for the measurement of en-
dotoxin levels in blood have been known for more than
40 years [2] and are based on the application of the LAL
endotoxin assay (Limulus Amebocyte Lysate). Recently,
a new method for assessing endotoxin concentration in
blood has been developed – the Endotoxin Activity
Assay (EAA) [3,4]. Experimental observations [4] re-
vealed that the results of EAA testing correlate with* Correspondence: da_popov@inbox.ru
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distribution, and reproduction in any mediumthe level of endotoxemia, as determined by the LAL
method: At EAA = 0.4, the endotoxin level is compara-
tively low, approximately 25–50 pg/mL, but with an
increase of EAA to 0.6, the endotoxin level rises to 100–
200 pg/mL.
EAA might be helpful in the early recognition of pa-
tients who are at high risk of developing severe sepsis and
septic shock. EAA levels lower than 0.4 represent a low
risk for the development of severe sepsis and in most
cases, confirm the absence of a severe gram-negative
infection. EAA values within the range of 0.4-0.59 are con-
sidered average and correspond to an increased risk of se-
vere sepsis. EAA levels of 0.6 and greater represent a high
risk of mortality and development of severe sepsis and
septic shock development. These data are reflected in the
integrated acute physiology and chronic health evaluation
score (APACHE II): a low EAA level corresponded to a
mortality of 10.9% and an APACHE II score of 13.3,
whereas an average and high EAA were associated with a
mortality of 13.2% and 16.8%, respectively, and APACHE
II scores of 15.3 and 17.6, respectively [4]. A prospectiveentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Yaroustovsky et al. Journal of Inflammation 2013, 10:8 Page 2 of 5
http://www.journal-inflammation.com/content/10/1/8study conducted by D. Klein et al. on 53 patients with
septic shock revealed a mortality of 16% at EAA levels
lower than 0.4 and 34% with EAA levels between 0.4 and
0.59. EAA levels greater than 0.6 corresponded to a mor-
tality increase of 50% and greater [5,6]. Moreover, EAA
testing provides an opportunity to estimate the effective-
ness of treatment.
Contemporary clinical practice entails the complex man-
agement of sepsis, including haemodynamic and respiratory
support, prevention of thromboembolism and gastrointes-
tinal bleeding, nutritional support, and therapy with ste-
roids [7]. In addition, detoxification therapy, together with
extracorporeal blood purification based on the application
of selective LPS-sorbents, seems to be useful [8,9].
Laboratory indicators of endotoxemia together with
clinical findings and data from other diagnostic methods
serve as criteria for the assessment of sepsis severity,
treatment effectiveness and outcomes. Investigations
that estimate the prognostic value of the EAA method
are currently lacking. So, aim of the study was to evalu-
ate the prognostic value of EAA in adult patients with
suspected or proven severe sepsis after cardiac surgery.
Methods
The study was approved by the Ethics Committee of
Bakoulev Scientific Centre for Cardiovascular Surgery.
Between November 2009 and February 2012, 3245 adult
patients underwent open-heart surgery in our Institute.
In a single-centre prospective observational study were
included 81/3245 (2.5%) patients with suspected orTable 1 Patient characteristics
Parameters Overall population, n = 81
Age, years 56 (47.5-64.5)
Male sex 45/81 (56%)
APACHE II scores 20 (10–30)
Renal failure 41/81 (50.6%)
Dialysis requirement 19/81 (23.5%)
Epinephrine Receivers 74/81 (91.4%)
Dose, mcg/kg/min 0.08 (0.05-0.1)
Dopamine Receivers 53/81(65.4%)
Dose, mcg/kg/min 5 (4–7)
Dobutamine Receivers 26/81(32%)
Dose, mcg/kg/min 5.75 (4–8)
Norepinephrine Receivers 12/81(14.8%)
Dose, mcg/kg/min 0.07 (0.05-0.1)
WBC, х109/l 13.2 (10.5-19.3)
LAL,EU/mL 0.72 (0.36-0.72)
РСТ, ng/mL 5.07 (1.25-13.72)
ЕАА 0.49 (0.39-0.66)
* between survivors and non-survivors.proven severe sepsis. Patients’ initial characteristics are
shown in Table 1.
The average age was 56 (47.5-64.5) years. Forty-five of
the patients underwent valvular surgery, whereas 12 under-
went combined myocardial revascularisation, 19 under-
went isolated surgery for coronary anomaly correction, 4
underwent surgery for hypertrophic cardiomyopathy ac-
companied by correction of left ventricular outflow tract
obstructions, and in 1 patient with dilated cardiomyopathy,
an orthotopic heart transplantation was performed.
The early postoperative period in all studied patients
was complicated by low cardiac output syndrome (LVEF
15-28%), which required inotropic support by two or more
sympathomimetic agents. In 10 cases, an intra-aortic
balloon pump was applied. The presence of respiratory
failure with poor gas exchange demanded prolonged
mechanical lung ventilation. Patients developed severe
sepsis on ICU day 7 on average (range: day 4–8), defined
as the development of systemic inflammatory response
syndrome (SIRS) combined with a suspected or proven
locus of bacterial infection alongside multiorgan dysfunc-
tion. The most common source was ventilator-associated
pneumonia, found in 66/81 (81%) patients and confirmed
by clinical, X-ray and laboratory data.
All patients received treatment for severe sepsis accor-
ding to approved guidelines [7], including antimicrobial
therapy in a de-escalation regimen adjusted by bacterio-
logical data.
After the onset of severe sepsis, clinical and laboratory
parameters were recorded as well as blood samples forSurvivors, n = 44 Non-survivors, n = 37 p-value*
53 (42–61) 59 (52–66) 0.06
23/44 (52%) 22/37 (59%) 0.67
11 (8–26) 28 (15–31) 0.0008
20/44 (45.5%) 24/37 (64.9%) 0.19
6/44 (13.6%) 13/37 (36.4%) 0.44
40/44 (90.9%) 34/37 (91.9%) 0.81
0.07 (0.05-0.1) 0.09 (0.06-0.1) 0.31
29/44 (65.9%) 24/37 (64.9%) 0.89
5.5 (5–8) 5 (3–6) 0.06
14/44(31.8%) 11/37(29.7%) 0.97
5.15 (4.25-7) 6 (4–8) 0.64
5/44(11.4%) 9/37(24.3%) 0.02
0.08 (0.05-0.15) 0.06 (0.05-0.09) 0.46
13 (10.6-20.8) 13.4 (10–18.9) 0.83
0.72(0.36-0.72) 0.72 (0.36-1.08) 0.65
3.06 (0.72-8) 5.69 (3.19-23.34) 0.05
0.45 (0.33-0.58) 0.6 (0.45-0.69) 0.009
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Endotoxin levels were assessed by means of the LAL test
(Biowhitakker, USA) and by EAA, which was carried out
by the luminol chemiluminescence method (Spectral
Diagnostics Inc, Canada). EAA is based on the principle
that endotoxin binds to antiendotoxin antibodies (IgM)
and is then delivered to neutrophils via complement
receptors. In the presence of zymosan and luminol, neu-
trophils undergo a respiratory burst accompanied by
light emission. The light produced is quantified by a
chemiluminometer, and its intensity is proportional to
the amount of endotoxin.
PCT plasma concentrations were measured by the
VIDAS B·R·A·H·M·S PCT test (bioMérieux, France).
To compare the predictive values of EAA, LAL-test,
PCT, and APACHE II, receiver operating characteristic
(ROC) curves were constructed, and the area under the
curve (AUC) was determined. The outcome variable was
28-day mortality.
Statistical analysis was performed with SPSS software,
version 20 (SPSS, Inc., Chicago, Ill). Discrete variables
were expressed as counts (percentage), and continuous
variables were expressed as a median and inter-quartile
range. Statistical differences between groups were
assessed with the Mann-Whitney U-test. Correlations
were determined with Spearman's rank method (two-
sided). P-values less than 0.05 were considered statisti-
cally significant.
Results
Clinical and laboratory data from studied patients are
shown in Table 1.
There were no significant differences between survi-
vors and non-survivors in terms of age, gender, rate of
renal failure, dialysis requirement, need for inotropic
support (except norepinephrine) and WBC count. APA-
CHE II scores were significantly higher in non-survivors.
In contrast to PCT and LAL-test results, levels of EAA
were significantly greater in deceased patients.
Forty-four of 81 studied patients (54%) had positive
bronchoalveolar lavage (BAL) cultures for various bacterial
species: Acinetobacter baumannii in 19 patients; Klebsiella
pneumoniae in 11 patients; Pseudomonas aeruginosa in
7 patients; and coagulase-negative Staphylococci in 7 pa-
tients. The same bacteria were responsible for positive
blood cultures, which were observed in 30 patients (37%):Table 2 Clinical and laboratory indices
Group ЕАА LAL,EU/mL
Group I, n = 20 0.3 (0.26-0.34) 0.36 (0.36-0.72)
Group II, n = 35 0.48* (0.44-0.52) 0.72 (0.36-0.72)
Group III, n = 26 0.69** (0.65-0.73) 0.72** (0.7-1.44)
* p I-II <0.05.
** p I-III <0.05.Klebsiella pneumoniae in 2 patients; Acinetobacter bau-
mannii in 10 patients; Pseudomonas aeruginosa in 5
patients; and coagulase-negative Staphylococci in 13 pa-
tients. The rate and spectra of positive BAL and blood cul-
tures were similar between survivors and non-survivors.
Patients were divided into 3 groups by EAA results:
EAA <0.4 (Group I, low EAA, n = 20); EAA between 0.4
and 0.59 (Group II, elevated EAA, n = 35); and EAA ≥
0.6 (Group III, high EAA, n = 26). Respective group data
are shown in Table 2.
Gram-negative bacteraemia was found in 19/55 (35%)
of cases with ЕАА less than 0.6 and in 11/26 (42%) of
cases with higher ЕАА (p = 0.67).
We obtained higher levels of blood plasma endotoxin,
measured by the LAL-test, as well as greater PCT con-
centrations, APACHE II scores and mortality in patients
with moderate and high EAA levels compared to pa-
tients with low EAA levels. These differences were sta-
tistically significant.
There was a moderate correlation of ЕАА with LAL-test
results and РСТ (r = 0.53, p = 0.002 and r = 0.27, p = 0.03
respectively). We did not find a correlation between LAL
test results and РСТ levels (r = 0.17, p =NS).
Also APACHE II scores correlated with EAA and PCT
(r = 0.33, p = 0.005 and r = 0.31, p = 0.01 respectively),
but not with LAL-test (r = 0.29, p = NS).
ROC analysis comparing the accuracy for the prediction
of 28-day mortality revealed areas under the receiver ope-
rating characteristics curve (AUC) for APACHE II scores,
EAA and PCT of 0.81, 0.73 and 0.66, respectively
(Figure 1). The optimal prognostic cut-offs (maximum
combined sensitivity and specificity) related to 28-day
mortality with corresponding values are listed in Table 3.
The AUC for EAA (0.73) was higher than the AUC for
PCT and lower that of APACHE II (0.66 and 0.81, re-
spectively). AUC for LAL was 0.5 (0.3-0.71), so we did
not calculate further characteristics for this marker.
Patients with EAA results higher than 0.65 had a 28-
day mortality that was significantly higher than those
with a lower EAA value (18/26 – 69% vs. 19/55 – 34.5%;
p = 0.0072).
Discussion and conclusions
Sepsis, severe sepsis and septic shock still represent ob-
stacles in modern medicine due to a high morbidity and
unacceptable mortality. Therefore, it is important toРСТ, ng/mL APACHE II 28-day mortality,%
3.49 (1.25-8.75) 10 (6–13) 20
3.68 (0.95-7.7) 15 (9–20.5) 43
9.3** (4.2-28.3) 30,5** (28–32) 54**
Figure 1 Receiver operating characteristic curve of serum levels of EAA, LAL, PCT and APACHE II in predicting 28-day mortality.
Yaroustovsky et al. Journal of Inflammation 2013, 10:8 Page 4 of 5
http://www.journal-inflammation.com/content/10/1/8introduce new diagnostic tools and therapeutic interven-
tions for the early recognition and treatment of patients
in such severe conditions.
It is well-known that the clinical signs and symptoms
of systemic inflammatory response syndrome (SIRS) are
non-specific, so the use of biomarkers such as PCT is
required. This marker, triggered mainly by LPS, IL-6 and
TNF-α, reflects the response of the macroorganism to a
bacterial load and can be used as an early, sensitive and
specific diagnostic tool, as well as to guide antibiotic
treatment [10].
Endotoxemia is a common finding in critically ill patients
and can originate either from a focal gram-negative infec-
tion or the gastro-intestinal tract due to dysfunction of its
barrier [11]. In our study, gram-negative bacteraemia was
observed in 19/55 (35%) of patients with an ЕАА < 0.6 and
only in 11/26 (42%) of cases with an ЕАА ≥ 0.6, which may
reflect the load from other sources, mainly the gut [12].Table 3 ROC analysis data
Parameter AUC (95% CI) Optimal cut-off value Se,% Sp,%
APACHE II 0.81 (0.66-0.96) 11.5 78 69
EAA 0.73 (0.55-0.92) 0.65 72 69
PCT 0.66 (0.45-0.87) 4.76 67 62
Se sensitivity, Sp specificity, AUC area under the curve.Endotoxin exposure can induce systemic inflammation,
progressing to sepsis that results in shock and multiorgan
failure. Taking all of this into consideration, it is important
to have the opportunity to measure the blood levels of
LPS, which can guide therapy (e.g., LPS adsorption to pre-
vent or attenuate the inflammatory response).
For many years, the detection of bacterial endotoxin was
performed by the LAL-test. This method has some serious
limitations; one of the most important is a poor specificity
for LPS [13]. The endotoxin activity assay may provide an
opportunity to perform a prompt and objective assessment
of endotoxin concentration in a patient’s blood.
We found that EAA significantly correlates with LAL-
test results (r = 0.53, p = 0.002) and with PCT (r = 0.27,
p = 0.03). This may be explained by the fact that the im-
mune response functions as a trigger, and the presence of
LPS in the blood will not necessarily lead to activation
of the inflammatory cascade and the development of
systemic inflammation. That is why the application of
methods to detect endotoxin, together with markers of
the macroorganism response (e.g., PCT), yielded the best
results.
Monti et al. published data on the interaction between
ЕАА and prognosis in critically ill septic shock patients.
According to that study, all patients with low endotoxin
activity (<0.4) survived. Patients with intermediate (be-
tween 0.4 and 0.6) and high (≥0.6) EAA levels had a
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obtained in the present study allow us to assume that
endotoxin activity levels exceeding 0.65 indicate increased
28-day mortality and in the presence of other clinical signs
of severe infection. AUCs for APACHE II and EAA as a
predictors of 28-day mortality were higher, than for PCT
which can be used as a criterion to initiate specific treat-
ment, including earlier introduction of selective LPS ad-
sorption into the treatment complex.
Early selective haemoperfusion with a polymyxin B
cartridge (PMX) improves the results of complex inten-
sive therapy for sepsis and multiorgan failure [9]. It was
shown that EAA can be used as a criterion for the initi-
ation of LPS adsorption procedures to decrease the 28-
day mortality in patients with severe sepsis from 75% to
45.5% [15]. During this treatment, EAA levels decrease,
which reflects the effectiveness of endotoxin removal
from the blood of patients with sepsis. Other studies
found a similar reduction in ICU mortality (from 45% to
16%, p = NS due to small sample size) and improvement
in the clinical condition of septic shock patients who re-
ceived adjuvant therapy with PMX [16]. A reduction in
the endotoxin activity level by 33–80% was also demon-
strated in the last European multicentre randomised
controlled trial, “EUPHAS” [17].
Determining endotoxin activity by EAA allows the se-
lection of patients at the highest risk of developing se-
vere infections as well as predicting the outcome. This
marker gives an early indication for specific intensive
therapy for sepsis and facilitates the evaluation of its
effectiveness.
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